ClinicalTrials.gg
CompletedNCT07179354CLASSIII-3DUpdated Sep 23, 2025

Comparative 3D Assessment of Class III Malocclusion Treatments

An interventional study of Rapid Maxillary Expansion with Face Mask (RME/FM) and Mini Maxillary Protractor (MMP) in Class III Skeletal Malocclusion, sponsored by TC Erciyes University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 9 Months to 12 Months. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Feb 2024, registered Sep 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
9 Months to 12 Months
Sex
All
01

Study summary

This clinical trial compares three different treatment methods used to correct jaw problems in children with Class III malocclusion (a condition where the lower jaw is positioned forward relative to the upper jaw). The treatments include:

Rapid maxillary expansion with face mask (RME/FM),

Mini maxillary protractor (MMP),

Modified splints with elastics and chin cup (SEC III).

The study aims to understand how each treatment affects the bones and soft tissues of the face, such as how much the upper jaw moves forward or the lower jaw moves backward, as well as changes in teeth alignment and facial appearance. Results showed that different treatments work best for different aspects: some are better for moving the upper jaw forward, while others are better for repositioning the lower jaw. This information helps doctors choose the most suitable treatment plan for each patient.

Read the detailed description

This prospective randomized controlled clinical trial evaluates and compares the skeletal and three-dimensional soft tissue effects of three orthopedic treatment protocols in growing patients with Class III skeletal malocclusion. A total of 43 patients were randomly assigned to one of three treatment groups: rapid maxillary expansion with face mask (RME/FM), mini maxillary protractor (MMP), and modified splints with elastics and chin cup (SEC III). Additionally, a control group was formed from archival records of untreated patients with similar malocclusion characteristics.

Patients underwent comprehensive evaluation before and after treatment, including lateral cephalometric radiographs and 3D stereophotogrammetry to capture skeletal and soft tissue changes. Key parameters measured were maxillary and mandibular skeletal movements, dental inclination changes, overjet and overbite adjustments, as well as facial soft tissue displacement and angular measurements.

The study's design ensured rigorous randomization and controlled conditions to objectively assess the efficacy of each treatment protocol. The outcomes provide insight into how each method influences skeletal advancement or retrusion, dental positioning, and facial profile alterations, offering guidance for personalized treatment planning in orthodontic practice.

02

Conditions studied

  • Class III Skeletal Malocclusion

Keywords

  • Class III malocclusion
  • RME/FM
  • Mini maxillary protractor
  • SEC III
  • 3D stereophotogrammetry
  • Soft tissue
  • Cephalometry
03

In context

Malocclusion, Angle Class III

57 studies on the registry are indexed under Malocclusion, Angle Class III; 11 are open to participants now.

This study's enrollment of 55 is above the median of 32 across 53 interventional studies indexed under Malocclusion, Angle Class III.

Browse Malocclusion, Angle Class III studies →

Lead sponsor

TC Erciyes University is the lead sponsor of 349 studies on the registry; 74 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who have not completed their growth spurt (9-12 years old)
  • Overjet ≤ 0 mm (patients with negative overjet must be De Nevreze positive)
  • ANB ≤ 0°, Witts \< 1
  • Good oral hygiene and healthy periodontal tissues
  • SN-GoGn angle between 26° and 38°
  • No congenital or acquired tooth loss (excluding third molars)
  • (BMI) between 18-26 kg/m²
  • No systemic, local, or endocrinological diseases

Exclusion criteria

Exclusion Criteria:

  • Presence of any syndrome or developmental deformity
  • Previous orthodontic treatment
  • Allergy to any metal or acrylic
  • Presence of any systemic disease affecting treatment
  • SN-GoGn angle > 38°
  • Presence of temporomandibular joint disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    RME/FM Group (Rapid Maxillary Expansion with Face Mask)

    Participants in this group received rapid maxillary expansion using a bonded expander, followed by protraction with a face mask. This protocol aims to advance the maxilla in patients with Class III skeletal malocclusion.

    Device: Rapid Maxillary Expansion with Face Mask (RME/FM)

  • Experimental
    MMP Group (Mini Maxillary Protractor)

    This group was treated with the Mini Maxillary Protractor (MMP), a custom-designed intraoral appliance used to achieve orthopedic maxillary protraction without external devices. The aim is to promote maxillary advancement in growing Class III patients.

    Device: Mini Maxillary Protractor (MMP)

  • Experimental
    Modified SEC III Group (Modified Splints with Elastics and Chin Cup)

    Participants in this group were treated using modified splints with intermaxillary elastics and a chin cup (SEC III protocol). The protocol is designed to restrict mandibular growth and enhance maxillary positioning in patients with skeletal Class III malocclusion.

    Device: Modified Splint with Elastics and Chin Cup (Modified SEC III)

  • No intervention
    Control Group (Untreated group selected from archival records)

    This group includes untreated patients with Class III skeletal malocclusion, selected from archival records. No intervention was administered. The group serves as a baseline comparison for evaluating treatment effects.

Interventions

  • DeviceRapid Maxillary Expansion with Face Mask (RME/FM)

    A tooth- and tissue-borne rapid maxillary expansion appliance with an expansion screw was used to achieve transverse maxillary expansion, followed by Petit-type face mask therapy. Expansion protocol: two quarter-turns per day for 10-14 days, then one quarter-turn per day until cusp-to-cusp relationship was achieved. Face mask elastics applied 16 hours/day at 350-500 g per side, with a 30° downward and forward vector relative to the occlusal plane.

  • DeviceMini Maxillary Protractor (MMP)

    An intraoral mini maxillary protraction appliance was used to advance the maxilla. Force was applied through intraoral elastics connected to intraoral anchorage units. The protocol was designed to deliver orthopedic forward traction of the maxilla without an external face mask.

  • DeviceModified Splint with Elastics and Chin Cup (Modified SEC III)

    A modified splint appliance combined with intraoral elastics and an orthopedic chin cup was used to achieve skeletal mandibular retrusion and Class III correction. The appliance applied orthopedic forces through combined vertical and horizontal components, promoting backward positioning of the mandible while maintaining transverse maxillary relationships.

06

What researchers measure

Primary outcomes

  1. Three-dimensional changes in soft tissues

    3D stereophotogrammetry used to assess overall soft tissue profile changes, including facial convexity and lip-chin parameters.

    Time frame: baseline to post-treatment (≈ 9 months)

Secondary outcomes

  1. Two dimensional changes in skeletal parameters of the maxilla and mandible

    Lateral cephalometric radiographs used to evaluate overall skeletal changes in maxillary and mandibular positions, as well as dental parameters including overjet and overbite.

    Time frame: Baseline (pre-treatment) to post-treatment (≈ 9 months)

07

Study locations

1 site
  • Erciyes University, Faculty of Dentistry, Department of Orthodontics
    Kayseri, 38039, Turkey (Türkiye)
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the dataset is limited to a small number of pediatric patients and was collected solely for internal academic research purposes.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jan 2025, 10 months.

Of 37 non-industry interventional studies with no phase under Malocclusion, Angle Class III, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.

Counting every sponsor, half of 38 studies reached it within 13 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 17, 2025
StartActual
Feb 21, 2024
Primary completionActual
Jan 9, 2025
CompletionActual
Mar 3, 2025
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07179354
Responsible party
Gokhan Coban (Associate Professor, TC Erciyes University) — Principal investigator
First posted
Sep 17, 2025
Start date
Feb 21, 2024
Primary completion
Jan 9, 2025
Completion
Mar 3, 2025
Last update
Sep 23, 2025

Study contacts

Gökhan Çoban, Associate Professor, PhD,
principal investigator · Erciyes University, Faculty of Dentistry, Department of Orhodontics
Tuba Ünlü Çiftçi, Research Assistant
principal investigator · Erciyes University, Faculty of Dentistry, Department of Orhodontics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion